Acarbose decreases liver fat
Acarbose is a diabetes drug that blocks the ability of the digestive enzyme amylase to break down starch in the small intestine.
In a small 12 week randomized controlled trial in women with polycystic ovary syndrome (PCOS), acarbose significantly decreased liver fat, as well as blood levels of triglycerides and free fatty acids (FFA’s).
In comparison, treatment with metformin or a lower calorie diet did not decrease liver fat, and did not decrease triglycerides or FFA’s.
Note that these results are in line with a recent RCT showing that replacing refined starch one-for-one with resistant starch decreases liver fat. See this post: ↪ Swapping refined starch for resistant starch halved liver fat in 4 months in an RCT. Acarbose essentially turns most starch into resistant starch by blocking its breakdown in the small intestine.
Quoted:
“In a 12-week, randomized, open tag prospective clinical trial, we recruited thirty obese PCOS patients, and randomly divided them into three groups: LCD [low calorie diet], metformin, and acarbose group. Body weight, adipose tissue distribution, and serum sex hormone levels were measured before and after treatment. MRI was used to measure the liver fat content (LFC) and abdominal fat mass (AFM).”
“In all three groups, AFM [abdominal fat mass] and insulin secretion were significantly decreased as measured by MRI, OGTT and glucose clamp, respectively.”
“Interestingly, we found only acarbose significantly decreased triglyceride, FFAs [free fatty acids], and LFC [liver fat content].”
“All treatment modalities were effective in the treatment of PCOS women with obesity and IGT [impaired glucose tolerance], only acarbose significantly decreased the triglyceride and FFAs, and ameliorated the LFC [liver fat content], suggesting that acarbose is an effective agent that could be used in PCOS patients with IGT and fatty liver.”
Paper · DiabetesP Lifestyle Intervention Metformin anddiabetesjournals.org#liverfatHD #acarboseHD #pcosHD #resistantstarchHD #amylaseHD




